Skip to main content

Human Clinical Study: Immune Health

In a study involving 44 participants aged 20-62, researchers observed after four weeks of daily consumption of the probiotic DE111 at 1 billion CFU a significant decrease in the basal levels of several immune cell populations, including CD3+ T cells,…

Human Clinical Study: Children’s GI Health

In a study involving 81 children aged 2 to 6, researchers found that that daily consumption of the probiotic strain Bacillus subtilis DE111 supported a healthy gastrointestinal tract with a reduced duration of vomiting, hard stools, and overall gastrointestinal discomfort. VIEW PUBLISHED…

Human Clinical Study: Children’s Microbiome & Immune Health

In a study involving 91 children aged 2 to 6, researchers found that daily consumption of the probiotic strain Bacillus subtilis DE111 positively modulated the gut microbiome profile without changing the overall microbiome equilibrium. After 8 weeks of daily probiotic consumption at…

Human Clinical Study: Cardiovascular Health

In a study involving 43 participants aged 18 to 65, researchers found that B. subtilis DE111 supplementation of 1 billion CFU per day resulted in significant reduction in total cholesterol and non-HDL cholesterol relative to baseline measures. The team also…

Human Clinical Study: Athletic Recovery

In a study involving male collegiate athletes during offseason training, researchers found that DE111 (1 billion CFU), in conjunction with adequate post-workout nutrition, can promote tissue recovery and reduce likelihood of injury. The results of the study showed that compared…

Human Clinical Study: Sports Performance And Body Composition

In a study involving female collegiate athletes during offseason training, researchers found that DE111 (1 billion CFU), in conjunction with adequate post-workout nutrition, can improve body composition and indices of athletic performance. The results of the study showed that compared…

Human Clinical Study: DE111 Supports Regularity

A clinical study showed a reduction of alternating constipation and diarrhea for the participants taking DE111 (1 billion CFU) when compared to participants taking the placebo. The proportion of normal stools (types 3 and 4) increased from 54% to 64%…